Ligand Pharmaceuticals Incorporated LGND
313.52 USD +6.50 (+2.12%)
At closeNov 3, 2026, 4:02 PM EST
313.53 +0.01 +0.00%
After hours · Nov 3, 4:02 PM ET
309.46 Day range 317.76
175.89 52-week range 326.63
- YTD
- +65.82%
- 1 year
- +63.94%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 350.92 +11.9% upside
Now 313.52
- Target (low)
- 247.00
- Target (mean)
- 350.92
- Target (high)
- 406.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.87 | 2.43 – 3.07 | 2.02 | +41.9% | 96.72M | +62.1% | 10 |
| Next quarter | 2.31 | 2.30 – 2.31 | 1.63 | +41.5% | 76.14M | +47.2% | 2 |
| Current year | 9.49 | 9.25 – 9.74 | 8.13 | +16.8% | 291.35M | +8.7% | 10 |
| Next year | 12.21 | 10.51 – 13.46 | 9.49 | +28.6% | 381.00M | +30.8% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 25, 2026 | Barclays | Initiated | — | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 14, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 3, 2026 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jul 15, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 9, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jul 8, 2026 | Stifel | Maintained | Buy | Buy |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 28, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 15, 2026 | Citigroup | Maintained | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 11, 2026 | B of A Securities | Initiated | — | Buy |
| Feb 27, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 10, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Dec 10, 2025 | Stifel | Maintained | Buy | Buy |
| Dec 9, 2025 | Citigroup | Initiated | — | Buy |
| Nov 10, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 7, 2025 | Benchmark | Maintained | Buy | Buy |
| Nov 7, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 2, 2025 | Benchmark | Maintained | Buy | Buy |